Navigation Links
TGen Drug Development establishes European footprint
Date:11/19/2009

SCOTTSDALE, Ariz. Nov. 18, 2009 TGen Drug Development (TD2) and the Institut Paoli-Calmettes (IPC) have forged a strategic alliance that will enable both to maximize their worldwide contributions in the treatment of cancer patients.

The partnership between TD2, a Scottsdale subsidiary of the Phoenix-based Translational Genomics Research Institute (TGen), and Marseille, France-based IPC's comprehensive cancer center will enable both non-profit institutes to speed research discoveries to patients with cancer.

Both organizations will expand their clinical research network to evaluate new therapies in the U.S. and Europe in an effort to more quickly introduce new drugs into clinical trials.

Teams from both TD2 and IPC will focus their efforts on discovering molecular alterations within cancers and finding biomarkers that will help identify new therapeutic targets that can be used to tailor treatments for individual patients.

IPC and TD2 will collaborate on a number of primary tumor and metastasis in selected cancers, as well as initiate an exchange program for medical oncologists between the two institutions.

"Aligning with IPC represents a significant opportunity for TD2 and TGen to further expand our research affiliations into Europe," said Dr. Daniel Von Hoff, TGen's Physician-In-Chief. "In addition to our ongoing collaborations with Luxembourg, this new alliance with IPC will further our goals across both Europe and the United States of providing better treatments in a more timely fashion to our many patients who suffer from a variety of cancer types."

Professor Patrice Viens, a medical oncologist and General Director of IPC, said the alliance with TD2 will enable IPC to bridge new international relationships: "This alliance with TD2 translates to our continuing efforts to expand our collaborations in basic research and medical activities beyond Europe.''

IPC is one of the largest university-affiliated comprehensive cancer centers in France, involved in the management of nearly 6,000 new cases of cancer each year. IPC established a Biological Resource Center (BRC) in oncology that has 70,000 tumor and biological fluid samples, mostly of breast, pancreatic and blood cancers. ICP had more than 600 patients in clinical trials during 2008.

IPC is affiliated with the Ovarian Cancer Diagnosis Initiative (OVCAD), which is dedicated to ovarian cancer research, and with the European Consortium for Anticancer Antibody Development (EUCAAD), a European consortium dedicated to anti-angiogenic treatments. It also is involved in collaborations with biotech and pharmaceutical companies.

IPC will join TGen's Pancreatic Cancer Research Team (PCRT), which includes other U.S. and international researchers.

"Our meetings at TGen have confirmed our decision to team up with this premier organization on the cutting edge of research and pharmacogenomics in oncology," Professor Viens said. "In addition we are thrilled to work again with Dr. Von Hoff." Professor Viens and Dr. Von Hoff once worked together at the University of Texas Health Science Center in San Antonio, Texas.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Gender, coupled with diabetes, affects vascular disease development
2. New target for anti-flu drug development
3. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
4. KAUST and American University in Cairo to collaborate on research and academic development
5. Old developmental pathways spawn revolutionary evolutionary changes
6. NIST announces 56 new awards for innovative technology research and development
7. Progress Against Malaria: Developments on the Horizon
8. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
9. Biopharmaceutical infrastructure key to lower drug development costs
10. Study identifies pathway required for normal reproductive development
11. 200 journals join in theme issues on poverty and human development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Feb. 9, 2016 Aware, Inc. (NASDAQ: AWRE ), ... results for its fourth quarter and year ended December 31, 2015.  ... the fourth quarter of 2015 was $6.9 million, an increase of ... Operating income in the fourth quarter of 2015 was $2.6 million ... --> --> Higher revenue and ...
(Date:2/8/2016)... 2016 Worldcore is ... innovation for clients, comfort and unbeatable security, with ... --> Worldcore is the first EU-regulated ... comfort and unbeatable security, with a Voice Biometrics ... Worldcore is the first EU-regulated global payment ...
(Date:2/4/2016)... 4, 2016 The field of Human ... the most popular hubs of the biotechnology industry. ... huge studies of human microbiota, have garnered a ... the microbiome space has literally exploded in terms ... This report focuses on biomedical aspects of research, ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: ... pleased to announce that Mitsui & Co. Ltd., its ... succinic acid plant, is investing an additional CDN$25 million ... increasing its stake from 30% to 40%.  Mitsui will ... bio-succinic acid produced in Sarnia , ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal ... its proprietary NeXosome® technology for early warning of ... its most recent study by Dr. Thomas ... the Society for Maternal Fetal Medicine,s (SMFM) annual meeting ... 1-6 th , 2016.  The presentation reported initial ...
(Date:2/10/2016)... (NYSE MKT: ISR), a medical technology company and innovator ... treatment of prostate, brain, lung, head and neck and ... second quarter and six months of fiscal 2016, which ... --> Revenue was $1.19 million for ... 31, 2015, a 12% increase compared to $1.07 million ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... announced today the promotion of two long-standing principal investigators (PI) to the roles ... Clinical Research and Development. , Dr. Laurence Chu, a Benchmark Research PI in ...
Breaking Biology Technology: